Kiniksa Pharmaceuticals International, plc

KNSA Nasdaq SEC CIK 1730430
Follow Kiniksa Pharmaceuticals International Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $286M +58.1% vs same quarter last year
Net income $47.3M +156.8% vs same quarter last year
EPS, diluted $0.56 +143.5% vs same quarter last year
Operating cash flow $47.5M +41.2% vs same quarter last year
Revenue by quarter
$122.5M
$137.8M
$156.8M
$180.9M
$202.1M
$214.3M
$243.6M
$286M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income10 fiscal years
  • Revenue
  • Net income
−$250M$0$250M$500M$750MFY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$677.6M$59M
FY24$423.2M−$43.2M
FY23$270.3M$14.1M
FY22$220.2M$183.4M
FY21$38.5M−$157.9M
FY20-−$161.4M
FY19-−$161.9M
FY18-−$103.2M
FY17-−$64.9M
FY16--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−600%−400%−200%0%200%FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2588.5%11.4%8.7%
FY2485.6%−10.8%−10.2%
FY2387.6%−9.3%5.2%
FY2289.6%4.4%83.3%
FY2176.4%−406.4%−409.7%
FY20---
FY19---
FY18---
FY17---
FY16---
Free cash flowOperating cash flow minus capital expenditure
−$200M−$100M$0$100M$200MFY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25$136.4M
FY24$25.4M
FY23$13.2M
FY22$5.7M
FY21−$126.7M
FY20−$136.8M
FY19−$161.6M
FY18−$86.3M
FY17−$50.3M
FY16-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Kiniksa Pharmaceuticals International
  • Healthcare median
−600%−400%−200%0%200%FY17FY19FY21FY23FY25
Show the numbers
YearKiniksa Pharmaceuticals InternationalHealthcare median
FY258.7%−30.6%
FY24−10.2%−47%
FY235.2%−58%
FY2283.3%−80.4%
FY21−409.7%−71.8%
FY20-−62.2%
FY19-−46.2%
FY18-−49.6%
FY17-−45.9%
FY16-−36%